1. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms. (2nd September 2017) Authors: Pazina, Tatiana; James, Ashley M.; MacFarlane, Alexander W.; Bezman, Natalie A.; Henning, Karla A.; Bee, Christine; Graziano, Robert F.; Robbins, Michael D.; Cohen, Adam D.; Campbell, Kerry S. Journal: Oncoimmunology Issue: Volume 6:Number 9(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗